Exosens Stock: Bernstein Raises Price Target to 71 Euros
Exosens stock closed on Wednesday, January 28 at 53.60 euros, down 0.37% for the session. The stock of the critical technology specialist has nevertheless shown a remarkable increase of 144.1% over the year, despite a consolidation of 5.8% over the last seven days. This dynamic comes as the group benefits from renewed interest from financial analysts.
The Bernstein research office made two consecutive adjustments to its recommendation on Exosens in January. On January 16, the analyst initiated coverage with an outperform rating and a price target of 61 euros, before revising this target to 71 euros on January 19, while maintaining its favorable opinion. This new estimate gives the stock a potential appreciation of 32.5% compared to the closing price on January 28. The increase in the target reflects increased confidence in the group's prospects, following an exceptional stock market performance over twelve months. The outperform rating highlights the appeal of the case in the eyes of the American broker, in a context where the defense technology sector is attracting sustained investor interest.
Technical Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, Exosens is slightly below its 20-day moving average, positioned at 54.66 euros, indicating a pause after a strong quarterly rise of 14.9%. The 14-period RSI stands at 43, signaling a neutral zone without overbuying or overselling, following the weekly correction. The one-month volatility, measured at 11.08, remains moderate given the range of movements observed over the past year. This technical breather occurs in a context where the stock has increased its value by 2.4 times in twelve months. The proximity to the 20-day moving average now serves as a short-term benchmark for traders.
Nous sommes fiers de présenter notre performance sur les neuf premiers mois de l’année 2025, qui témoignent d'une croissance soutenue du chiffre d'affaires et de la marge brute ajustée, portée par la forte dynamique du secteur de la Défense.
Marché de la Défense très dynamique, forte demande pour la vision nocturne et les systèmes pour drones/anti-drones, croissance soutenue en Europe avec contribution des États-Unis et de l’Asie-Pacifique. Lancement commercial réussi des tubes 5G (plus de 5 000 commandes avant lancement).
Risks mentioned
Cession de l’activité Amplification par Micro-ondes entraînant une perte comptable sans impact de trésorerie en 2025
Dépendance aux budgets de Défense et aux évolutions géopolitiques
Risque d'intégration des acquisitions récentes
Incertitudes de la demande dans les Sciences de la Vie (marché américain)
Opportunities identified
Croissance adressable liée à la vision nocturne et aux applications drones/anti-drones
Commercialisation des tubes 5G avec commandes significatives (>5 000 tubes)
Expansion des capacités de production (+40% d’ici 2027) soutenant le développement commercial
Effets de croissance externe (Noxant, NVLS, Phasics) élargissant le marché adressable
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
